Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed an 8-K current report with the SEC on May 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Worldwide exclusive license gives Rigel development, manufacturing, and commercialization rights for approved breast-cancer drug VEPPANU.
RIGEL PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Worldwide exclusive license gives Rigel development, manufacturing, and commercialization rights for approved breast-cancer drug VEPPANU
- $70M upfront payment plus $15M after specified transition activities, creating near-term cash obligations
- Up to $320M in regulatory and sales milestones, including $260M tied to net-sales thresholds
- Tiered royalties in the mid-teens to mid-twenties, plus sublicense-revenue sharing, potentially limiting product economics
- Rigel may reimburse up to $40M of Pfizer development costs; agreement awaits HSR antitrust clearance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RIGEL PHARMACEUTICALS INC 8-K filings
Get the next RIGL 8-K as it lands
Follow RIGL for push alerts, or ask the research agent what this filing means.